Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 6 Y. X; u5 N$ K' Y
+ c- l V9 _# K: \% F
1 U1 k9 S0 z. t1 U! Q- NSub-category:3 Y7 |' m- [$ L% K% a
Molecular Targets
d/ h5 g- j9 m+ ^- z9 s' ` O
7 F6 z6 N: Y5 `* P3 S
% {" V: K) D" V1 qCategory:1 K/ d! ?# u! a1 \# [: j8 H) W I
Tumor Biology
0 B+ n( t7 r$ I. K) K9 h* g6 v( x9 E O& r' F8 d t
7 r- J# e9 S1 \
Meeting:
3 x6 @$ z, n+ M4 |2 o% R) @6 F3 i2011 ASCO Annual Meeting 5 G! B0 t$ ~/ o) ]5 j
- j! p* Q; L1 u* }/ F* {( f
5 P: X1 p& x" L, x2 {9 A. ]2 S. X0 zSession Type and Session Title:3 M4 }6 B g2 H* X# a; e7 h
Poster Discussion Session, Tumor Biology
+ U3 T; P! i5 v* f- T6 u8 o/ G) G" a% R
7 |9 I6 v: q) m5 e7 yAbstract No:" d! E$ E0 ?4 s0 B, t$ {
10517 ( t. I6 D. j5 a
: M6 }2 O3 i y! M& J x8 z2 u: ]2 W" M
Citation:
+ D' d) q! w: O( hJ Clin Oncol 29: 2011 (suppl; abstr 10517)
5 c: s: l, F" n6 t
: }# F% y& C- c% n! I* P. @! w5 s1 N5 e, t1 x4 g I$ S9 J' E" {
Author(s):6 ^7 f8 O8 |7 X+ e
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 J" Q: s; C: H, t$ ]; `) {2 |# d! s3 O5 H O, t
. P8 L) _& u- a
2 m' z) n& s- o ^$ n3 T/ Q1 YAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.+ b# q5 ~3 s5 \& ]+ h/ w
& K: i6 m! \! s* l; ]* fAbstract Disclosures7 C& o: c1 P+ t- e( L% _( _- G
+ q4 C N V2 g( h* ^# s2 y/ A" ^5 d
Abstract:
4 g6 |+ g/ S7 G0 S: E; S
- C6 R- U( z- b* U5 j2 w5 G, G/ A4 t
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 q; Y5 ]9 ~! |3 _* K- z4 d( d5 h& f, {1 i
H6 S/ U l7 D8 O |